期刊
CANCER JOURNAL
卷 17, 期 5, 页码 343-350出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e318233e5b2
关键词
Peptide; neoplasm; melanoma; immune therapy; TLR agonists; vaccine; cancer vaccine
类别
资金
- National Institutes of Health/National Cancer Institute [R01 CA118386, R01 CA57653]
- Commonwealth Foundation for Cancer Research
- James and Rebecca Craig Foundation
- University of Virginia Cancer Center
- Alice and Bill Goodwin, Frank and Jane Batten, the James and Rebecca Craig Foundation
Peptide vaccines incorporate one or more short or long amino acid sequences as tumor antigens, combined with a vaccine adjuvant. Thus, they fall broadly into the category of defined antigen vaccines, along with vaccines using protein, protein subunits, DNA, or RNA. They remain one of the most immunogenic approaches, based on measures of T-cell response in the blood or in draining lymph nodes. However, existing peptide vaccines have had limited success at inducing clinical tumor regressions, despite reliable induction of T-cell responses. Several new developments offer promise for improving peptide vaccines, including use of long peptides, optimization of adjuvants including toll-like receptor agonists, and combination with systemic therapies that may reduce tumor-associated immune dysfunction, such as blockade of PD-1/PD-L1 interactions. To apply these new approaches optimally, it will be critical to study their effects in the context of defined antigens, for which peptide vaccines are optimal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据